ABCL Overview

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Wall Street analysts forecast ABCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABCL is9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Abcellera Biologics Inc revenue for the last quarter amounts to 44.85M USD, increased 788.18

Abcellera Biologics Inc. EPS for the last quarter amounts to -0.03 USD, decreased -75.00

Abcellera Biologics Inc (ABCL) has 562 emplpoyees as of April 20 2026.

Today ABCL has the market capitalization of 1.22B USD.